We are live on
!
Find out more
PBA
Paradigm Biocapital Advisors Portfolio holdings
AUM
$4.89B
1-Year Est. Return
251.12%
This Fund
S&P 500
This Quarter
Est. Return
+32.84%
1 Year Est. Return
+251.12%
3 Year Est. Return
+670.11%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$4.89B
AUM Growth
+$976M
(+25%)
Cap. Flow
+$388M
Cap. Flow
% of AUM
7.92%
Top 10 Holdings %
Top 10 Hldgs %
67.65%
Holding
40
New
10
Increased
13
Reduced
7
Closed
5
Top Buys
| 1 |
Insmed
INSM
|
+$193M |
| 2 |
BLTE
Belite Bio
BLTE
|
+$187M |
| 3 |
MAZE
Maze Therapeutics
MAZE
|
+$121M |
| 4 |
Cytokinetics
CYTK
|
+$94.1M |
| 5 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$91.4M |
Top Sells
| 1 |
CDTX
Cidara Therapeutics
CDTX
|
+$168M |
| 2 |
Crinetics Pharmaceuticals
CRNX
|
+$103M |
| 3 |
Scholar Rock
SRRK
|
+$82.3M |
| 4 |
ABVX
Abivax
ABVX
|
+$76.3M |
| 5 |
UroGen Pharma
URGN
|
+$55.5M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Lexeo Therapeutics
LXEO
$368M
| $35.5M | 0.73% |
6,184,134
+1,420,936
| +30% | +$10.1M |
|
|
MANE
27
Veradermics Inc
MANE
$4.65B
| $33.2M | 0.68% |
+525,000
| New | +$26.5M |
|
28
Vor Biopharma
VOR
$980M
| $31.2M | 0.64% |
1,750,000
| – | – |
|
|
29
UroGen Pharma
URGN
$1.96B
| $30.6M | 0.63% |
1,703,949
-2,769,699
| -62% | -$55.5M |
|
30
Structure Therapeutics
GPCR
$3.45B
| $26.3M | 0.54% |
+545,287
| New | +$37.3M |
|
|
IVA
31
Inventiva
IVA
$1.09B
| $22.2M | 0.45% |
4,000,000
| – | – |
|
32
Oric Pharmaceuticals
ORIC
$1.11B
| $21.6M | 0.44% |
1,701,217
-700,000
| -29% | -$7.95M |
|
33
Assembly Biosciences
ASMB
$531M
| $18.5M | 0.38% |
665,251
| – | – |
|
|
BBOT
34
BridgeBio Oncology
BBOT
$686M
| $7.77M | 0.16% |
868,213
-1,393,536
| -62% | -$15M |
|
|
KLRS
35
Kalaris Therapeutics
KLRS
$104M
| $4.04M | 0.08% |
700,000
| – | – |
|
36
BridgeBio Pharma
BBIO
$15.9B
| – | – |
-684,277
| Closed | -$52.3M |
|
|
CDTX
37
DELISTED
Cidara Therapeutics
CDTX
| – | – |
-759,565
| Closed | -$168M |
|
|
38
Crinetics Pharmaceuticals
CRNX
$8.88B
| – | – |
-2,210,774
| Closed | -$103M |
|
39
Ocular Therapeutix
OCUL
$1.96B
| – | – |
-2,935,284
| Closed | -$35.6M |
|
40
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
| – | – |
-1,500,000
| Closed | -$183M |
|
Similar funds
KCM
DGI
FC
WTC
MCM
MSRPS
MCCA
MWM
Paradigm Biocapital Advisors's Q1 2026 Portfolio in Review
As of Q1 2026, Paradigm Biocapital Advisors held 40 positions worth $4.89B, up 25% from $3.92B the previous quarter. Its ten largest holdings account for 68% of the portfolio.
Paradigm Biocapital Advisors deployed $388M of net new capital in Q1 2026, opening 10 new positions and adding to 13 existing holdings. Its largest new stake was Insmed: 1,254,488 shares worth $205M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 95% a quarter earlier.
On the sell side, the largest reduction was Scholar Rock, an estimated $82.3M trimmed.
- Paradigm Biocapital Advisors's largest Q1 2026 buy was Insmed: 1,254,488 shares worth $205M.
- Paradigm Biocapital Advisors added most to Terns Pharmaceuticals in Q1 2026, an estimated $57.8M increase.
- Paradigm Biocapital Advisors's biggest Q1 2026 reduction was Scholar Rock, cutting an estimated $82.3M.
- Paradigm Biocapital Advisors fully exited Cidara Therapeutics in Q1 2026, selling an estimated $168M.
- Paradigm Biocapital Advisors's ten largest holdings make up 68% of its $4.89B portfolio in Q1 2026.
- Paradigm Biocapital Advisors opened 10 new positions and closed 5 in Q1 2026.
- Paradigm Biocapital Advisors's portfolio value rose 25% quarter-over-quarter to $4.89B.
Based on Paradigm Biocapital Advisors's 13F filing for Q1 2026, filed 15 May 2026.